Print Friendly Page
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
This research study is being done to see if an investigational drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread (metastatic disease) from its original site (the prostate) to other parts of the body. 18F-DCFPyL targets a specific protein which is seen in prostate tumors.
The investigation of 18F-DCFPYL will be done by conducting three small studies. The first two studies will attempt to see if 18F-DCFPYL can be used to more accurately diagnose prostate cancer and identify the stage of the cancer. The first study will enroll men newly diagnosed with prostate cancer and the second will enroll men that have already had their prostate cancer surgery but have rising PSA level on blood test. The third study will include men who have other imaging tests (CT, MRI, PET, US) to see if the prostate cancer has spread to other parts of their body after treatment with hormonal therapy.
- Proven diagnosis of Prostate Cancer
- PSA greater than 1.0
- Imaging evidence of suspected metastatic disease including CT, bone scan, MRI, ultrasound or other PET modalities
Applicable Disease Sites
UW Hospital and Clinics